Bulletin
Investor Alert

New York Markets Open in:

Market Snapshot Analyst Ratings

INmune Bio Inc.

NAS: INMB

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
INmune Bio Inc.

Market closed

 --Quotes are delayed by 20 min

Sep 26, 2023, 4:00 p.m.

INMB
/zigman2/quotes/206182062/composite

$

7.00

Change

-0.08 -1.13%

Volume

Volume 41,015

Quotes are delayed by 20 min

/zigman2/quotes/206182062/composite

Previous close

$ 7.08

$ 7.00

Change

-0.08 -1.13%

Day low

Day high

$6.92

$7.32

Open

52 week low

52 week high

$5.75

$11.26

Open
Income Statement Balance Sheet Cash Flow Statement

Annual Financials for INmune Bio Inc.

View Ratios
Fiscal year is January-December. All values USD millions. 20182019202020212022 5-year trend
Sales/Revenue --10,916181,000374,000
Cost of Goods Sold (COGS) incl. D&A -----
COGS excluding D&A -----
Depreciation & Amortization Expense -----
Depreciation -----
Amortization of Intangibles -----
Gross Income -----
20182019202020212022 5-year trend
SG&A Expense 12.44M7.76M12.24M29.33M26.33M
Research & Development 1.11M3.28M5.92M20.54M17.07M
Other SG&A 11.33M4.47M6.32M8.79M9.26M
Other Operating Expense -----
Unusual Expense -----
EBIT after Unusual Expense -----
Non Operating Income/Expense --128,520(1.19M)(1.35M)
Non-Operating Interest Income -77,688---
Equity in Affiliates (Pretax) -----
Interest Expense -----
Gross Interest Expense -----
Interest Capitalized -----
Pretax Income (12.44M)(7.68M)(12.1M)(30.34M)(27.3M)
Income Tax -----
Income Tax - Current Domestic -----
Income Tax - Current Foreign -----
Income Tax - Deferred Domestic -----
Income Tax - Deferred Foreign -----
Income Tax Credits -----
Equity in Affiliates -----
Other After Tax Income (Expense) -----
Consolidated Net Income (12.44M)(7.68M)(12.1M)(30.34M)(27.3M)
Minority Interest Expense -----
Net Income (12.44M)(7.68M)(12.1M)(30.34M)(27.3M)
Extraordinaries & Discontinued Operations -----
Extra Items & Gain/Loss Sale Of Assets -----
Cumulative Effect - Accounting Chg -----
Discontinued Operations -----
Net Income After Extraordinaries (12.44M)(7.68M)(12.1M)(30.34M)(27.3M)
Preferred Dividends -----
Net Income Available to Common (12.44M)(7.68M)(12.1M)(30.34M)(27.3M)
EPS (Basic) (1.28)(0.75)(1.01)(1.88)(1.52)
Basic Shares Outstanding 9.74M10.27M11.99M16.13M17.93M
EPS (Diluted) (1.28)(0.75)(1.01)(1.88)(1.52)
Diluted Shares Outstanding 9.74M10.27M11.99M16.13M17.93M
EBITDA -(7.76M)(12.23M)(29.15M)(25.95M)
Copyright 2023 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Link to MarketWatch's Slice.